INT264991

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 2008
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.22
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Tnfsf11) extracellular space (Tnfsf11) extracellular region (Tnfsf11)
plasma membrane (Tnfsf11) intracellular (Tnfsf11) cytoplasm (Tnfsf11)
Anatomy Link Frequency
osteoblasts 6
stromal cells 2
osteoclast 2
Tnfsf11 (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 4 95.84 Very High Very High Very High
cytokine 12 82.60 Quite High
antagonist 14 57.28 Quite High
Inflammatory response 4 48.00 Quite Low
imagery 10 31.20 Quite Low
Pain 36 5.00 Very Low Very Low Very Low
analgesia 2 5.00 Very Low Very Low Very Low
Spinal cord 1 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 84 100.00 Very High Very High Very High
Hypercalcemia 31 97.32 Very High Very High Very High
Osteolysis 101 84.64 Quite High
Metastasis 45 84.24 Quite High
Osteoporosis 34 82.36 Quite High
Reprotox - General 1 26 79.60 Quite High
Multiple Myeloma 10 70.56 Quite High
Foreign Bodies 4 64.08 Quite High
INFLAMMATION 4 47.64 Quite Low
Pain 36 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The RANK–RANKL pathway is inhibited by a soluble competitor of RANKL, osteoprotegerin (OPG), which is secreted by the same cell population (osteoblasts and stromal cells) in response to different stimuli (estradiol, TGF-?
Positive_regulation (response) of Localization (secreted) of RANKL in osteoblasts
1) Confidence 0.24 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.41 Pain Relevance 0.13
The RANK–RANKL pathway is inhibited by a soluble competitor of RANKL, osteoprotegerin (OPG), which is secreted by the same cell population (osteoblasts and stromal cells) in response to different stimuli (estradiol, TGF-?
Positive_regulation (response) of Localization (secreted) of OPG in osteoblasts
2) Confidence 0.21 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.40 Pain Relevance 0.12
This hypothesis postulates that factors such as PTHrP [26], RANKL [27] and IL-8 [28] are secreted by cancer cells and stimulate osteoclast recruitment and activity.
Positive_regulation (stimulate) of Localization (secreted) of RANKL in osteoclast associated with cancer
3) Confidence 0.11 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3020964 Disease Relevance 1.59 Pain Relevance 0.09
The RANK–RANKL pathway is inhibited by a soluble competitor of RANKL, osteoprotegerin (OPG), which is secreted by the same cell population (osteoblasts and stromal cells) in response to different stimuli (estradiol, TGF-?
Positive_regulation (response) of in stromal cells Localization (secreted) of RANKL in osteoblasts
4) Confidence 0.08 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.41 Pain Relevance 0.13
The RANK–RANKL pathway is inhibited by a soluble competitor of RANKL, osteoprotegerin (OPG), which is secreted by the same cell population (osteoblasts and stromal cells) in response to different stimuli (estradiol, TGF-?
Positive_regulation (response) of in stromal cells Localization (secreted) of OPG in osteoblasts
5) Confidence 0.07 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.40 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox